Sam Brusco, Associate Editor12.06.23
Tandem Diabetes Care has launched updated t:slim X2 insulin pump software with Dexcom G7 continuous glucose monitoring (CGM) integration in the U.S.
Tandem said its automated insulin delivery (AID) system with Control-IQ technology is the only AID option today to use Dexcom’s latest CGM technology. The company will email instructions to in-warranty t:slim X2 users in the U.S. to offer the option to add the feature without charge via a remote software update.
“With this launch we are offering more than 300,000 current t:slim X2 users the ability to integrate with Dexcom’s most advanced CGM technology, demonstrating our commitment to continued leadership in advancing AID systems,” Tandem’s president and CEO John Sheridan told the press. “As we celebrate our 10-year partnership with Dexcom, we remain committed to sustaining our rapid pace of innovation to further our mission of helping improve the lives of people with diabetes.”
By integrating Dexcom G7, t:slim X2 pump users can spend more time in closed-loop with little to no wait time between G7 sensor sessions. G7 is 60% smaller than its G6 predecessor and features improved accuracy, 30-minute sensor warmup time, and a 12-hour grace period to replace finished sensors.
“The Dexcom G7 and t:slim X2 insulin pump integration is the culmination of years of partnership and a shared commitment to improve the lives of people with diabetes,” said Dexcom executive VP and COO Jake Leach. “We’re excited to bring our newest technology to Tandem users so they can experience the benefits of the smallest, most accurate, easy to use CGM connected to AID systems..
Tandem said its automated insulin delivery (AID) system with Control-IQ technology is the only AID option today to use Dexcom’s latest CGM technology. The company will email instructions to in-warranty t:slim X2 users in the U.S. to offer the option to add the feature without charge via a remote software update.
“With this launch we are offering more than 300,000 current t:slim X2 users the ability to integrate with Dexcom’s most advanced CGM technology, demonstrating our commitment to continued leadership in advancing AID systems,” Tandem’s president and CEO John Sheridan told the press. “As we celebrate our 10-year partnership with Dexcom, we remain committed to sustaining our rapid pace of innovation to further our mission of helping improve the lives of people with diabetes.”
By integrating Dexcom G7, t:slim X2 pump users can spend more time in closed-loop with little to no wait time between G7 sensor sessions. G7 is 60% smaller than its G6 predecessor and features improved accuracy, 30-minute sensor warmup time, and a 12-hour grace period to replace finished sensors.
“The Dexcom G7 and t:slim X2 insulin pump integration is the culmination of years of partnership and a shared commitment to improve the lives of people with diabetes,” said Dexcom executive VP and COO Jake Leach. “We’re excited to bring our newest technology to Tandem users so they can experience the benefits of the smallest, most accurate, easy to use CGM connected to AID systems..